Investigation of changes in the levels of circulating MDSC with progression of PC and after the immunotherapy [104] showed high percentage of CD14+/HLA-DRl°/− monocytic MDSC in treated PC (30.7 ± 15.0% of CD14+ cells) compared to untreated PC (10.6 ± 14.3%, p = 0.0001) patients. The gene discussed is CD14; the disease is pachyonychia congenita.